InvestorWire NewsRoom

Article

BioPharma Site Solutions Nexus to Focus on Overcoming Obstacles in Research Trial Site Management
October 14, 2024

BioPharma Site Solutions Nexus to Focus on Overcoming Obstacles in Research Trial Site Management

Innovation in scientific research, that attempts to address some of the most challenging diseases of the modern era, depends largely on the biopharmaceuticals industry’s ability to establish and sustain viable clinical research trial sites.

Test research sites are often beset by difficulties ranging from high participant dropout rates to funding constraints. Clinical research managers are tasked with addressing stringent regulatory compliance, maintaining data integrity, and ensuring that research staff are adequately trained and supported to keep them engaged in the research and successful in achieving the best outcomes possible.

The BioPharma Nexus Conference series’ Site Solutions Nexus event will directly address solutions to issues surrounding these challenges, drawing on the expertise of professionals working for some of the most significant companies in the pharmaceutical and biotech sphere.

Among the more than a dozen presenters at the two-day event, in the heart of one of the world’s most prestigious research communities, are invited guests from Bristol Myers Squibb, Johnson & Johnson’s Janssen Pharmaceutical Companies, Japan’s giant Daiichi Sankyo, and Botox and autoimmune drug developer AbbVie.

The conference is a critical opportunity to network with peers in the industry amid an environment conducive to scientific advancement. Attendees can build meaningful partnerships with other professionals, connect with networked influencers, and share in discussions about fresh ideas for businesses.

In its third year, the Site Solutions Nexus conference is building a reputation for addressing bottleneck issues that could otherwise stymie effective progress in medical research goals. The Oct. 22-23 conference will feature 18 speaker presentations, four panel discussions, and four roundtable gatherings, during full days of addressing research site needs.

BioPharma Nexus’ conferences build business ties between pharmaceutical and biotech companies and their service providers, addressing a wide array of issues in conference events sited in the United States and Europe to advance the quality of healthcare services available to patients worldwide.

Key takeaways: 

  • Located at one of the world’s most renowned research hubs
  • Experienced, professional speakers presenting on timely topics
  • Roundtable and panel discussions provide forums for networking and group learning

For more information about this event and to register, please visit https://ibn.fm/Kozo6.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).